218 related articles for article (PubMed ID: 38268028)
1. Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments.
Salort-Campana E; Solé G; Magot A; Tard C; Noury JB; Behin A; De La Cruz E; Boyer F; Lefeuvre C; Masingue M; Debergé L; Finet A; Brison M; Spinazzi M; Pegat A; Sacconi S; Malfatti E; Choumert A; Bellance R; Bedat-Millet AL; Feasson L; Vuillerot C; Jacquin-Piques A; Michaud M; Pereon Y; Stojkovic T; Laforêt P; Attarian S; Cintas P
Orphanet J Rare Dis; 2024 Jan; 19(1):24. PubMed ID: 38268028
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
[TBL] [Abstract][Full Text] [Related]
3. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
[No Abstract] [Full Text] [Related]
4. A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy.
Powell JC; Meiling JB; Cartwright MS
Muscle Nerve; 2024 Feb; 69(2):179-184. PubMed ID: 38040488
[TBL] [Abstract][Full Text] [Related]
5. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
[TBL] [Abstract][Full Text] [Related]
6. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
Oskoui M; Day JW; Deconinck N; Mazzone ES; Nascimento A; Saito K; Vuillerot C; Baranello G; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Papp G; Gorni K; Kletzl H; Martin C; McIver T; Scalco RS; Staunton H; Yeung WY; Fontoura P; Mercuri E;
J Neurol; 2023 May; 270(5):2531-2546. PubMed ID: 36735057
[TBL] [Abstract][Full Text] [Related]
7. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
9. Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction.
Bjelica B; Wohnrade C; Cespedes I; Osmanovic A; Schreiber-Katz O; Petri S
BMC Neurol; 2024 Feb; 24(1):67. PubMed ID: 38368338
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
11. Global Risdiplam Compassionate Use Program for Patients with Type 1 or 2 Spinal Muscular Atrophy.
Kantaria R; Baker K; Beckley-Kartey S; Gorni K; Montrocher-Ober I; Vindevoghel L
Clin Ther; 2024 Apr; 46(4):374-378. PubMed ID: 38461122
[TBL] [Abstract][Full Text] [Related]
12. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
13. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
[TBL] [Abstract][Full Text] [Related]
14. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
15. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
Markati T; Fisher G; Ramdas S; Servais L
Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
[TBL] [Abstract][Full Text] [Related]
16. One Year of Newborn Screening for SMA - Results of a German Pilot Project.
Vill K; Kölbel H; Schwartz O; Blaschek A; Olgemöller B; Harms E; Burggraf S; Röschinger W; Durner J; Gläser D; Nennstiel U; Wirth B; Schara U; Jensen B; Becker M; Hohenfellner K; Müller-Felber W
J Neuromuscul Dis; 2019; 6(4):503-515. PubMed ID: 31594245
[TBL] [Abstract][Full Text] [Related]
17. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST
Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265
[TBL] [Abstract][Full Text] [Related]
18. Risdiplam: A Review in Spinal Muscular Atrophy.
Paik J
CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
[TBL] [Abstract][Full Text] [Related]
19. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
[TBL] [Abstract][Full Text] [Related]
20. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy.
Osmanovic A; Ranxha G; Kumpe M; Müschen L; Binz C; Wiehler F; Paracka L; Körner S; Kollewe K; Petri S; Schreiber-Katz O
J Neurol; 2020 Aug; 267(8):2398-2407. PubMed ID: 32361837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
